We are representing a health system in the Northeast in a DEA investigation that spawned from a significant diversion at its largest hospital. We have assisted in investigating the diversion and reporting to various agencies, preparing for subsequent onsite inspections, and producing documents to DEA and state agencies. In addition, we have advised on the implementation of expansive compliance improvements in controlled substance processes across the system as a demonstration of the system’s commitment to diversion prevention. Negotiations with a U.S. Attorney’s Office arising from the DEA’s investigation are ongoing.